Search

Displaying results 2041 - 2050 of 5392 in total
  1. Drug

    ADX-10061

    go.drugbank.com/drugs/DB05419
    Experimental

    ADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.

  2. Drug

    Bemiparin

    go.drugbank.com/drugs/DB09258
    ApprovedInvestigationalWithdrawn

    These heparins have lower anti-thrombin activity than the traditional low molecular weight heparins and act mainly on factor-Xa, reducing the risk of bleeding due to selectivity for this specific clotting

    Products: HIBOR 2500 IU/0,2 ML KULLANIMA HAZIR 2 ENJEKTOR, HIBOR 2500 IU/0,2 ML KULLANIMA HAZIR 10 ENJEKTOR
  3. Drug

    Allogeneic Cardiosphere-Derived Cells

    go.drugbank.com/drugs/DB15744
    Investigational

    TNFa, IFN-y, IL-1B, and IL-15). The anti-inflammatory effects of CDC work through polarizing macrophages and restoring tissue function.

  4. Drug

    ISS-1018

    go.drugbank.com/drugs/DB05463
    Investigational

    ISS 1018 signals through Toll-like receptor 9 (TLR9) to induce the production of immunoglobulin by B cells and interferon (IFN) -alpha, IFN-beta, interleukin-12 (IL-12), and tumor necrosis factor - alpha

  5. Drug

    NP-50301

    go.drugbank.com/drugs/DB05662
    Experimental

    It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S.

  6. Drug

    Itopride

    go.drugbank.com/drugs/DB04924
    Investigational

    Itopride is a dopamine D2 antagonist with acetylcholinesterase inhibitory actions.

  7. Drug

    Vandetanib

    go.drugbank.com/drugs/DB05294
    ApprovedInvestigational

    Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectabl...

  8. Drug

    Equine Botulinum Neurotoxin E Immune FAB2

    go.drugbank.com/drugs/DB13897
    Approved

    Equine Botulinum Neurotoxin E Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype E. It is intravenously administered for the treat...

  9. Drug

    Equine Botulinum Neurotoxin C Immune FAB2

    go.drugbank.com/drugs/DB13898
    Approved

    Equine Botulinum Neurotoxin C Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype C. It is intravenously administered for the treat...

  10. Drug

    WNY0824

    go.drugbank.com/drugs/DB23606
    Experimental

    [A274253] It is a dual inhibitor of PLK-1 and BRET-4, which have both been found to be involved in CRPC via suppression of AR/MYC-mediated transcription. [A274258]